Pulmonary arterial hypertension (PAH) is a rare, debilitating and rapidly progressive disease.
Although there have been important medical advances in PAH management, the search …

Therapies that target the prostacyclin pathway are considered effective, yet are complex to
dose and may cause dose-limiting side effects for patients with pulmonary arterial …

Objective B-cell expansion is a key feature of Sjögren’s syndrome (SS). Accordingly, several
studies have reported the benefits of B-cell depletion with anti-CD20 monoclonal antibody (…

Objective To evaluate the rate of and potential risk factors for bloodstream infections (BSIs)
using data from the REVEAL (Registry to Evaluate Early and Long-term Pulmonary Arterial …

BACKGROUND Despite the development of advanced therapies for pulmonary arterial
hypertension, pregnancy remains contraindicated in these patients owing to high maternal and …

The management of pulmonary arterial hypertension (PAH) has become more complex in
recent years because of increased pharmacotherapy options and longer patient survival with …

BACKGROUND: Epoprostenol and treprostinil are intravenous prostacyclin medications
used to treat pulmonary arterial hypertension (PAH). This survey explored hospital policies …

Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a
relevant issue. Being IL-6 a key cytokine for B cell survival, the interleukin-6 (IL-6) −174G>C …

Rituximab selectively targets the B‐cell compartment, including rheumatoid factor‐positive
B cells. Short‐term efficacy and safety of rituximab in rheumatoid arthritis (RA) has been …

The availability of new medications has improved exercise capacity, enhanced quality of life,
and extended time to clinical worsening in patients with pulmonary arterial hypertension (…